Have you or has someone you know been diagnosed with Gleason 3+4 prostate cancer?
They may qualify to participate in our clinical trial.
Focal ablation may be an alternative to surgery and radiation
We are currently enrolling patients nationwide for participation in San Antonio, TX, Sarasota, FL and Seattle, WA.
MagForce will cover Travel Expenses and Study related costs.
Have you been diagnosed with Gleason 3+4 prostate cancer?
Learn more about our unique ablation technology
MagForce® USA, Inc. is conducting a clinical study evaluating NanoTherm® in the ablation of prostate cancer.
What is NanoTherm® Therapy?
NanoTherm® is an investigational treatment that uses magnetic nanoparticles and an alternating magnetic field to create heat and local ablation of the cancer lesion.
About this study
After screening, treatment with NanoTherm® requires two appointments over a week. After completing the treatment, you will have follow-up visits at 1 week, 1 month, and 4 months. Find this study on clinicaltrials.gov using NCT05010759.
What are the benefits for me?
If your therapy is a success, you may be able to return to Active Surveillance and not require immediate definitive treatment.
Compensation of up to $3,500 if all long-term follow up visits are completed.
MagForce® USA will cover the costs of study related travel, meals and lodgings.
Participate in the Study
We are currently enrolling participants for our Stage 2-B Study to be conducted in the Spring of 2022.
To qualify you should:
• Be 40 to 85 years of age
• Have a diagnosis of prostate cancer from a biopsy (Gleason 3+4)
• Have no metallic implants below your shoulders
For more information, complete the contact form and we will contact you for an evaluation to confirm eligibility.